Tell your U.S. senators: Stop prescription drug patent abuse
The patent system belongs to the American people and exists for our benefit. It’s been critical to spurring valuable innovation in medicine — but unfortunately there exist a number of loopholes that drug companies regularly exploit to abuse the patent system and maintain monopoly prices for their drugs.Take Humira, Abbvie’s brand-name drug to treat rheumatoid arthritis, for example: Humira cost $523 per month in 2002. In 2023, it costs $3,167 per month.Over the next few weeks, the U.S. Senate will be voting on measures to end drug patent abuse tactics. You can make a difference right now by sending an urgent message to your U.S. senators supporting strong federal-level reforms to the patent system.